---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-023226"
form_type: "8-K"
ticker: "ATRA"
cik: "0001604464"
company_name: "Atara Biotherapeutics, Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T03:41:22.261474+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Atara gets positive CHMP opinion for Ebvallo; Q3 net loss $84.1M

## Summary
- CHMP positive opinion for Ebvallo in EBV+ PTLD; EC approval expected by end 2022.
- Cash $265.4M; expects operating runway into Q1 2024 with Pierre Fabre milestone.
- Q3 net loss $84.1M ($0.82/diluted share) vs $84.7M ($0.90) YoY; R&D $70.2M.
- ATA188 MRI data show less brain atrophy, potential remyelination in progressive MS patients with CDI.
- Tab-cel safety consistent; ORR 51.2% in Phase 3 ALLELE; seeking US commercialization partner.

## SEC filing metadata
- accession: 0000950170-22-023226
- form_type: 8-K
- ticker: ATRA
- cik: 0001604464
- company_name: Atara Biotherapeutics, Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604464/000095017022023226/0000950170-22-023226-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604464/000095017022023226/atra-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-023226
- JSON: https://secwatch.observer/filing/0000950170-22-023226.json
- Plain text: https://secwatch.observer/filing/0000950170-22-023226.txt

## Key facts
- Earnings Releases
  Atara Biotherapeutics, Inc. reported financial results for the third quarter 2022.
  - Period: the third quarter 2022
  - Result: reported results
  source text: Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the third quarter 2022, recent business highlights, and key upcoming catalysts.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000095017022023226/0000950170-22-023226-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.